EUCTR2009-016836-11-GB进行中（未招募）1 期
A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma - PETEY
OSI Pharmaceuticals LLC0 个研究点目标入组 25 人开始时间: 2011年1月26日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion Criteria:
- •Patients must have recurrent or refractory ependymoma or subependymoma and be >= 1 year to <= 21 years of age at the time of randomization/study entry;
- •Performance status: Lansky >=50% for patients <=10 years of age; or Karnofsky 5>=0% for patients > 10 years of age; and
- •Measurable disease.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria:
- •Must not have previously received an EGFR-targeted therapy;
- •Must not have previously received oral etoposide;
- •Must not have received craniospinal radiotherapy within 24 weeks of randomization/study entry or involved field radiotherapy to the target lesion within 12 weeks of randomization/study entry; focal radiation to areas of symptomatic metastatic disease must not be given within 14 days
研究者
相似试验
进行中（未招募）
1 期
Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205 - Erlotinib in paediatric ependymoma patients previously treated with etoposideRecurrent or Refractory EpendymomaMedDRA version: 15.0Level: PTClassification code 10014967Term: EpendymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023478-38-GBOSI Pharmaceuticals LLC4
已完成
2 期
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2Non-Small Cell Lung CancerNCT00085839OSI Pharmaceuticals103
进行中（未招募）
1 期
A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancersPIK3CA-mutated solid cancers including previously treated recurrent or metastatic HNSCCCancerISRCTN11595117F. Hoffmann-La Roche Ltd40
进行中（未招募）
不适用
A phase II, randomized trial with single agent trastuzumab or lapatinib in women with metastatic breast cancer iperexpressing HER2 - NDwomen with metastatic breast cancer iperexpressing HER2MedDRA version: 9.1Level: LLTClassification code 10065430MedDRA version: 9.1Level: LLTClassification code 10055113EUCTR2008-001916-18-ITAZIENDA OSPEDALIERA ORDINE MAURIZIANO
进行中（未招募）
1 期
Study evaluating weekly oral vinorelbine versus metronomic oral vinorelbine in patients with Non Small Cell Lung Cancer.EUCTR2014-003859-61-ESPIERRE FABRE MEDICAMENT165